COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,546 Articles (22,881 medRxiv, 8,665 bioRxiv)

Most recent first Previous |  Page 88: Articles 871-880  | Next

SARS-CoV-2-induced dysregulation in ADAR editing patterns persists post viral clearance in individuals with mild COVID-19
Nair, A. M., Piontkivska, H.
10.1101/2025.06.09.658648 — Posted: 2025-06-11
The Susceptibility of Airborne SARS-CoV-2 to Far-UVC Irradiation
Angel, D. M., Luhung, I., Santos Guedes de Sa, K., Peccia, J.
10.1101/2025.06.09.658611 — Posted: 2025-06-11
American mink as an animal model to study SARS-CoV-2 and vaccine response
Aaltonen, K., Virtanen, J., Kegler, K., Venkat, V., Kareinen, L., Korhonen, E. M., Niamsap, T., Malmgren, R., Korpela, J., Naves, R. A., Iso-Oja, M., Svenns, S., Haggvik, T., Ojala, E., Vapalahti, O., Peura, J., Sukura, A., Ritvos, O., Pasternack, A., Nordgren, H., Kant, R., Sironen, T.
10.1101/2025.06.10.658224 — Posted: 2025-06-11
Estimating Excess Mortality Among People Living with HIV/AIDS During the COVID-19 Pandemic in the USA
Hall, L., Chowell, G.
10.1101/2025.06.09.25329225 — Posted: 2025-06-10
COVID-19 Increases the Rate of Incident Hypertension: A Case-Control Cohort Time-to-Event Study
Goldhaber-Fiebert, J. D., Phillips, S. C., Lucas, K. D., Jacobsen, D. A., Studdert, D. M.
10.1101/2025.06.09.25329275 — Posted: 2025-06-10
COVID-19 Increases the Rate of Incident Diabetes: A Case-Control Cohort Time-to-Event Study
Goldhaber-Fiebert, J. D., Phillips, S. C., Lucas, K. D., Jacobsen, D. A., Studdert, D. M.
10.1101/2025.06.09.25329289 — Posted: 2025-06-10
Acute anaphylactic and multiorgan inflammatory effects of Comirnaty in pigs: evidence of spike protein mRNA transfection and paralleling inflammatory cytokine upregulation
Dezsi, L., Kokeny, G., Szeneasi, G., Revesz, C., Meszaros, T., Barta, B., Facsko, R., Szilasi, A., Bakos, T., Kozma, G. T., Dobos, A., Merkely, B., Radovits, T., Szebeni, J.
10.1101/2025.06.07.658379 — Posted: 2025-06-10
Optimal dose and safety of intravenous favipiravir in hospitalised patients with SARS-CoV-2 infection: a Phase Ib, open-label, dose-escalating, randomised controlled study
Rowland, T., FitzGerald, R., Challenger, E., Dickinson, L., Else, L., Walker, L., Hale, C., Shaw, V., Kelly, C., Lyon, R., Gibney, J., Dhamani, K., Irwin, M., Enever, Y., Tetlow, M., Wood, W., Reynolds, H., Chiong, J., Osanlou, O., Pertinez, H., Bullock, K., Greenhalf, W., Owen, A., Lalloo, D. G., Jacobs, M., Hiscox, J. A., Jaki, T., Mozgunov, P., Saunders, G., Griffiths, G., Khoo, S. H., Fletcher, T., the AGILE CST-6 study group
10.1101/2025.06.09.25329141 — Posted: 2025-06-09
The impact of the COVID-19 pandemic on end of life care in LTCFs in England: A qualitative study of LTCF staff experiences
Cotterell, N., Collingridge Moore, D.
10.1101/2025.06.09.25328142 — Posted: 2025-06-09
'It's like the spirit of the blitz': the impact of the COVID-19 pandemic on LTCF staff working relationships in England.
Collingridge Moore, D., Cotterell, N.
10.1101/2025.06.09.25328141 — Posted: 2025-06-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).